new drugs
neurological diseases


NEU² Partners: Fraunhofer IME ScreeningPort

Fraunhofer IME Screening Port

Schnackenburgallee 114
D-22525 Hamburg

The Fraunhofer IME ScreeningPort (IME-SP) was set up in July 2014, following the integration of the European ScreeningPort GmbH into the Fraunhofer Gesellschaft. The Fraunhofer is Europe's largest application-oriented research organization with a workforce of over 23,000 and currently operates a total of 67 institutes and research units. The ScreeningPort is a division within the Fraunhofer Institute of Molecular Biology and Applied Ecology IME, which is headquartered in Aachen, and conducts research in the field of applied life sciences from a molecular level to entire ecosystems.

The mission of IME-SP is to bridge the gap between basic academic research and the life sciences industry in the field of drug discovery and development. With state-of-the-art infrastructure at its location in Hamburg, established processes and innovative technologies, IME-SP positioned itself as a world-leading research partner for small-molecule screening.

The IME-SP directs its efforts onto the development of biological assay systems, high-throughput drug discovery (i.e. high-throughput screening, high-content screening and virtual screening), the identification of diagnostic biomarkers (including those used for companion diagnostics in preclinical/clinical studies) and pharmacological bioinformatics.

Ansprechpartner / Contact persons:

Prof. Dr. Carsten Claussen (CEO)
Tel.: +49 40 303764–277 
Fax: +49 40 303764–100 

Philip Gribbon PhD (CSO)
Tel.: +49 40 303764–271 
Fax: +49 40 303764–100 

Kontakt / Contact:

Zentrale / Main: 
Fraunhofer IME ScreeningPort
Tel.: +49 40 303764–0
Fax: +49 40 303764–100